Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1576008 | 0.95 | GPR119 (0.56) | GPR119FAAHHPGDKDM4EPKM | |
| SCHEMBL4982002 | 0.94 | GPR119 (0.51) | GPR119FAAHHPGDKDM4EPKM | |
| SCHEMBL8430037 | 0.94 | GPR119 (0.57) | GPR119FAAHHPGDKDM4EPKM | |
| SCHEMBL23499817 | 0.94 | GPR119 (0.57) | GPR119FAAHHPGDKDM4EPKM | |
| SCHEMBL7920172 | 0.92 | GPR119 (0.49) | GPR119FAAHHPGDKDM4EPKM | |
| SCHEMBL23006759 | 0.92 | GPR119 (0.49) | GPR119FAAHHPGDKDM4EPKM | |
| SCHEMBL2187082 | 0.92 | GPR119 (0.49) | GPR119FAAHHPGDKDM4EPKM | |
| SCHEMBL15085741 | 0.92 | GPR119 (0.59) | GPR119FAAHHPGDKDM4EPKM | |
| SCHEMBL310405 | 0.90 | HPGD (0.54) | GPR119FAAHHPGDKDM4EPKM | |
| SCHEMBL31662254 | 0.90 | HPGD (0.54) | GPR119FAAHHPGDKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 427 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637480-B2 | Heterocyclic compounds as sting modulators | BEONE MEDICINES I GMBH (CH) | 2026-05-26 | — | — | US | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12583818-B2 | Compound, preparation method thereof, and use thereof | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2026-03-24 | — | — | US | disclosed |
| EP-3526196-B1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4688779-A2 | NOVEL COMPOUNDS AND USES THEREOF | Acelink Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260035356-A1 | MODULATORS OF TYK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260001875-A1 | AMINOPYRIMIDINYL DERIVATIVES FOR THE TREATMENT OF PARKINSON'S DISEASE | UNIV DUNDEE (GB) | 2026-01-01 | — | — | US | disclosed |
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667467-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| WO-1997040051-A1 | FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-30 | — | — | WO | disclosed |
| US-5563158-A | CARDIOVASCULAR DISORDERS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-10-08 | — | — | US | disclosed |
| EP-0667773-A4 | FIBRINOGEN RECEPTOR ANTAGONISTS. | MERCK & CO INC (US) | 1996-09-25 | — | — | EP | disclosed |
| EP-0730590-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-09-11 | — | — | EP | disclosed |
| EP-0674623-A1 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-10-04 | — | — | EP | disclosed |
| EP-0667773-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1995-08-23 | — | — | EP | disclosed |
| WO-1995018111-A1 | COMPOUNDS CONTAINING BASIC AND ACIDIC TERMINI USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-07-06 | — | — | WO | disclosed |
| WO-1995014683-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-06-01 | — | — | WO | disclosed |
| WO-1994014776-A2 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-07-07 | — | — | WO | disclosed |
| WO-1994008577-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1994-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583818-B2 | Compound, preparation method thereof, and use thereof | TYRO3, TH, SRMS | GPR119 407/4885FAAH 3873/4885HPGD 3331/4885 |
| US-20260035356-A1 | MODULATORS OF TYK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | TYK2, CRBN, CSNK2A3 | GPR119 4253/4885FAAH 4246/4885HPGD 4645/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | GPR119 4198/4885FAAH 3564/4885HPGD 4873/4885 |
| US-20260001875-A1 | AMINOPYRIMIDINYL DERIVATIVES FOR THE TREATMENT OF PARKINSON'S DISEASE | LRRK2, XIAP, PARK7 | GPR119 3041/4885FAAH 4012/4885HPGD 4483/4885 |
| US-12637480-B2 | Heterocyclic compounds as sting modulators | STING1, IFNAR1, IRF3 | GPR119 320/4885FAAH 3075/4885HPGD 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.